Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes.

George Pavlidis,Sotirios Papageorgiou,Efthimia Bazani,Anthi Bouchla,Eirini Glezou,Konstantinos Gkontopoulos,Thomas P. Thomopoulos,Vasiliki Pappa,Demetrios V. Vlahakos

Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes.

2021

George Pavlidis
Sotirios Papageorgiou
Efthimia Bazani
Anthi Bouchla
Eirini Glezou
Konstantinos Gkontopoulos
Thomas P. Thomopoulos
Vasiliki Pappa
Demetrios V. Vlahakos

Renin–angiotensin system (RAS) blockade by angiotensin-converting enzyme inhibitors (ACEis) or angiotensin-receptor blockers (ARBs) has been related to anemia in various situations. We aimed to inv...

Keywords:

in patient
Myelodysplastic syndromes
Lower risk
Discontinuation
Erythropoiesis
Pharmacology
Renin–angiotensin system
Blockade
Medicine
Anemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations